GSK plc

LSE:GSK.L

Sector

🏥 Health Care

Industries

💊 Pharmaceuticals

🧬 Biotechnology

🔬 Clinical Trials

💊 Drugstores & Retail Pharmacies

🧴 Personal Care

Location

United Kingdom

Market Cap

USD 76.82 B

Share Price

USD 18.97

Avg Daily Volume

10,453,685

Change (1 day)

0.58%

Change (1 year)

-6.14%

Change (YTD)

12.61%

GSK plc Research and Development (R&D) Expenses for the year ending December 31, 2024: USD 8.01 B

GSK plc Research and Development (R&D) Expenses is USD 8.01 B for the year ending December 31, 2024, a 1.15% change year over year. Research and development (R&D) expenses are the costs associated with the development of new products, technologies, or improvements to existing products.

GSK plc Research and Development (R&D) Expenses for the year ending December 31, 2023 was USD 7.92 B, a 19.38% change year over year.
GSK plc Research and Development (R&D) Expenses for the year ending December 31, 2022 was USD 6.63 B, a -7.14% change year over year.
GSK plc Research and Development (R&D) Expenses for the year ending December 31, 2021 was USD 7.14 B, a 2.59% change year over year.
GSK plc Research and Development (R&D) Expenses for the year ending December 31, 2020 was USD 6.96 B, a 15.02% change year over year.

Quarterly
Annual
TTM

From:

To:

Zoom:

Key data

Date	Research and Development (R&D) Expenses	Revenue	Revenue	Gross Profit

LSE: GSK.L

GSK plc

CEO	Ms. Emma Natasha Walmsley
IPO Date	July 1, 1988
Location	United Kingdom
Headquarters	980 Great West Road
Employees	68,629
Sector	🏥 Health Care
Industries Pharmaceuticals 🧬 Biotechnology 🔬 Clinical Trials 💊 Drugstores & Retail Pharmacies 🧴 Personal Care

Description

GSK plc, together with its subsidiaries, engages in the creation, discovery, development, manufacture, and marketing of pharmaceutical products, vaccines, over-the-counter medicines, and health-related consumer products in the United Kingdom, the United States, and internationally. It operates through four segments: Pharmaceuticals, Pharmaceuticals R&D, Vaccines, and Consumer Healthcare. The company offers pharmaceutical products comprising medicines in the therapeutic areas, such as respiratory, HIV, immuno-inflammation, oncology, anti-viral, central nervous system, cardiovascular and urogenital, metabolic, anti-bacterial, and dermatology. It also provides consumer healthcare products in wellness, oral health, nutrition, and skin health categories. The company offers its consumer healthcare products in the form of nasal sprays, tablets, syrups, lozenges, gum and trans-dermal patches, caplets, infant syrup drops, liquid filled suspension, wipes, gels, effervescents, toothpastes, toothbrushes, mouthwashes, denture adhesives and cleansers, topical creams and non-medicated patches, lip balm, gummies, and soft chews. It has collaboration agreements with 23andMe; Lyell Immunopharma, Inc.; Novartis; Sanofi SA; Surface Oncology; Progentec Diagnostics, Inc.; Alector, Inc.; and CureVac AG., as well as strategic partnership with IDEAYA Biosciences, Inc. and Vir Biotechnology, Inc. The company was formerly known as GlaxoSmithKline plc and changed its name to GSK plc in May 2022. GSK plc was founded in 1715 and is headquartered in Brentford, the United Kingdom.